

Japan, Taiwan strengthen collaboration in healthcare and drug discovery

April 28, 2026 | News

Second MoU signed between Japan's iPark Institute and Taiwan's Industrial Technology Research Institute



Japan-based iPark Institute has signed a Memorandum of Understanding (MoU) with Taiwan's Industrial Technology Research Institute (ITRI) to strengthen Japan-Taiwan collaboration in the healthcare and drug discovery fields.

ITRI, one of Taiwan's largest public research institutions, has established strong networks with startups, academia, and hospitals across Taiwan, and is recognised for its strengths in venture investment and commercialisation support.

Under the MoU, the two organisations will leverage their respective networks to enhance collaboration between Japanese and Taiwanese startups, promote joint initiatives, and accelerate the creation of innovation.

The main areas of cooperation include:

- Strengthening startup collaboration and growth support
- Joint implementation of exhibitions, events, and inter-company collaboration programs
- Collaboration in clinical research, market validation, and regulatory affairs
- Exploration of cooperation in product development and manufacturing (CDMO)

Toshio Fujimoto, President & CEO of iPark Institute, commented, "Taiwan's biotechnology industry has developed strong research and development capabilities supported by a well-established manufacturing base and extensive clinical trial networks. Collaboration with ITRI will play an important role in advancing partnerships between Taiwan-origin biotech ventures and Japanese companies."

Maggie Lu, Director of the Biomedical Technology and Device Research Laboratories, said, "Through the signing of a MOU with iPark Institute, we aim to further strengthen collaboration with Japanese companies in the research and development of innovative pharmaceuticals and key technologies within Taiwan's industrial sector, thereby accelerating our international expansion. Furthermore, by combining the strengths of both Japan and Taiwan in the clinical and manufacturing fields, we will promote the joint development of the pharmaceutical industry and further strengthen our ties with the global pharmaceutical

market.”